Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.
Cancer Chemother PharmacolSep 24, 2026 (epub)
Robert Bell, Lisa M O'Brien, Eunice Yuen et al.
✦ AI-curated · Sources linked
In 30 seconds
This population pharmacokinetic analysis evaluated pirtobrutinib, a non-covalent BTK inhibitor, in 595 patients with hematological malignancies from the Phase 1/2 BRUIN study. The study found that at the recommended dose of 200 mg once daily, 96% of patients were expected to achieve over 90% BTK inhibition throughout the dosing interval.
Key findings
- The mean elimination half-life of pirtobrutinib was estimated at 18.8 hours.
- At 200 mg QD, the mean maximum drug concentration was 6460 ng/mL.
- Pirtobrutinib disposition was significantly influenced by body weight, renal function, and serum albumin.
Why it matters
Understanding the pharmacokinetics of pirtobrutinib is crucial for optimizing treatment strategies in patients with hematological malignancies, ensuring effective BTK inhibition while minimizing the need for dose adjustments.